Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIV001 Phase 1a in Healthy Volunteers
NCT05975047Phase 1Completed
- Sponsor
- Liveome
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LIV001 in ulcerative colitis (UC) (4 arms), sponsored by Liveome. Primary endpoints: Number of participants with adverse events (AEs) at 28 days, Number of participants with clinical laboratory abnormalities at 28 days and 2 more. Started Sep 2023; status: completed.
02
Drugs
LIV001
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05975047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975047.